The FDA launched an “Expedited Investigational New Drug (IND) Pilot” under Operation Trialblazer, aiming to shorten the timeline for first-in-human studies in the U.S. rather than starting trials abroad. The agency will accept applications from qualified research institutions paired with drug sponsors and conduct rolling reviews as parts of IND applications arrive. The FDA’s plan targets specialized early-stage trial expertise, with up to 10 qualified research institution–sponsor pairings expected and application deadlines set for Oct. 30. The agency cited recurring sponsor concerns about time and uncertainty when moving from scientific discovery to IND readiness. In the agency’s framing, faster U.S. onboarding is intended to counteract the growing tendency to use faster-moving regulatory environments in places like China and Australia for early clinical development. The pilot is designed to reduce bureaucratic friction while maintaining standards for clinical research. The move increases the likelihood that sponsors will restructure timelines and site selection for first-in-human work, potentially affecting global trial planning and early-phase regulatory strategy.